Home Online Features Lilly's baricitinib delivered high rates of hair regrowth for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS study
Lilly’s baricitinib delivered high rates of hair regrowth for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS study
HO
Press Releases
Eli Lilly and Company, Incyte, American Academy of Dermatology (AAD) Annual Meeting  
March 8, 2025

Lilly’s baricitinib delivered high rates of hair regrowth for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS study

Late-breaking results presented at AAD show 80% or more scalp hair coverage at Week 36 in 42.4% of adolescents receiving baricitinib 4 mg

logo salamanca press

Salamanca Press

email salamanca press
Local & Social